Maxime Verhoeven

165 Editorial; unravelling the cost of biological strategies in RA REFERENCES 1. Bijlsma, J. et al. Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial. Lancet 388 , 343–355 (2016). 2. Verhoeven, M. M. A. et al. Effectiveness and safety over 3 years after the 2-year U-Act-Early trial of the strategies initiating tocilizumab and / or methotrexate. Rheumatology 59 , 2325–2333 (2020). 3. Verhoeven, M. M. A. et al. Effect on costs and quality-adjusted life-years of treat-to-target treatment strategies initiating methotrexate, or tocilizumab, or their combination in early rheumatoid arthritis. 5 year economic evaluation. J. Rheumatol. 2020 Aug (epub ahead of print). 4. Autoriteit Consument & Markt. Sectoronderzoek TNF-alfaremmers . https://www.acm.nl/sites/ default/files/documents/2019-09/sectoronderzoek-tnf-alfaremmers.pdf (2019). 5. Zorginstituut Nederland. Medicijnkosten.nl. 6. Drummond, M. F., Sculpher, M. J., Claxton, K., Stoddart, G. L. & Torrance, G. W. Methods for the Economic Evaluation of Health Care Programmes . (Oxford University Press, 2015). 7. Escorpizo, R. et al. Worker productivity outcome measures in arthritis. J. Rheumatol. 34 , 1372–1380 (2007). 8. WHO Regional Office for Europe. Medicines reimbursement policies in Europe. https://www.euro. who.int/__data/assets/pdf_file/0011/376625/pharmaceutical-reimbursement-eng.pdf (2018). 9. Putrik, P. et al. Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country’s wealth? Ann. Rheum. Dis. 73 , 2010–2021 (2014). 8